 
       
Cover Page for ClinicalTrials.gov 
   
Sponsor name:  [CONTACT_458886] , Inc.  
NCT number : [STUDY_ID_REMOVED]  
Sponsor trial ID:  ANVS -2200 2 
Official title of study:  A Randomized, Double -Blind, Placebo -Controlled, Dose -Ranging, 
Multicenter Study of  Buntanetap in Participants with Mild to 
Moderate Alzheimer’s Disease  
Document type:  Protocol  
Document date:  September  25, 2023 
 
Protocol ANVS -[ZIP_CODE]  Ver. 3.1; 09-25-2023  
Confidential  Page 1 of 57 Protocol Title:  
A Randomized, Double -Blind, Placebo -Controlled, Dose -Ranging, Multicenter Study of 
Buntanetap in Participants  with Mild to Moderate Alzheimer’s Disease  
Protocol Short Title:  
A dose -ranging study to investigate efficacy of buntanetap in mild to moderate AD participants  
Protocol Number:   ANVS -2200 2 
Sponsor:   Annovis Bio , Inc., Berwyn, Pennsylvania  [ZIP_CODE] , [LOCATION_003]  
US IND Number:   72,[ADDRESS_586229] be informed that the information is privileged or 
confidential and may not be further disclosed by [CONTACT_476]. These restrictions on disclosure will apply 
equally to all future information  supplied to you, which is indicated as privileged or confidential. 
Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited.   
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 4 of 57   
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586230] OF ABBREVIATIONS  
5’UTR   5’ untranslated region αSYN  Alpha -synuclein  
αSYN                          Alpha Synuclein  
Aβ   Amyloid Beta  
AChE    Acetylcholinesterase  
AD   Alzheimer’s diseases  
ADAS -Cog  Alzheimer’s Disease Assessment Scale –Cognitive Subscale  
ADCS -ADL  Alzheimer's Disease Cooperative Study Activities of Daily Living 
Inventory  
ADCS -CGIC  Alzheimer’s Disease Cooperative Study Clinician’s Global Impression of 
Change  
AE   Adverse Event  
ANOVA  Analysis of variance  
APP Amyloid Precursor Protein           
ATC  Anatomical Therapeutic Chemical           
AUC  Area under the curve  
BChE  Butyrylcholinesterase  
BDNF  Brain derived neurotrophic factor  
BP Blood pressure  
CA Competent Authority  
CFR  Code of Federal Regulations  
cGMP  current Good Manufacturing Practice  
CI Confidence Interval   
CLBP  Chronic low back pa in 
Cmax  Maximum plasma and CSF concentration  
ChE Cholinesterase  
C-SSRS  Columbia Suicide Severity Rating Scale  
CNS  Central Nervous System  
CRO  Contract Research Organization  
CSF Cerebrospi[INVESTIGATOR_458816] -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 6 of 57 GI Gastrointestinal  
GRAS  Generally recognized as safe  
GWAS  Genome Wide Association Studies  
HbA1c  Hemoglobin A1C  
HEK 293  Human embryonic kidney cells  
HEENT  Head/ears/eyes/nose/throat  
hERG  Human ether -a-go-go related gene  
HIPAA  Health Insurance Portability and Accountability Act  
HPMC  Hydroxypropyl methylcellulose   
ICH International Conference on Harmonization  
IDMB  Independent Data Monitoring Board  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
IRE Iron-responsible element  
IRP1  Iron Regulatory Protein 1  
LAR  Legally authorized representative  
MAD  Multiple Ascending Dose  
MCI  Mild Cognitive Impairment  
MDS -UPDRS  MDS -United Parkinson’s Disease Rating Scale  
MedRA  Medical Dicti onary for Regulatory Activities  
mITT  modified Intent to Treat  
MMRM  Mixed model for repeated measures  
MMSE  Mini -Mental State Examination  
mRNA  Messenger Ribonucleic Acid  
NFL  Neurofilament light  
NG Neurogranin  
NIA National Institute on Aging  
NIA-AA National Institute on Aging and Alzheimer’s Association  
NIH National Institutes of Health  
NOAEL  No observed adverse effect level  
NPH  Normal Pressure Hydrocephalus  
OHRP  Office for Human Research Protections  
p-tau  Phosphorylated tau  
PD Parkinson’s disease   
PHI Prote cted Health Information  
PI [INVESTIGATOR_458817]1 Presenilin 1  
QD Once a Day  
QID 4 Times a Day  
QT Interval seen in electrocardiogram (ECG) test  
QTc  Interval seen in QT (ECG) test  
RA Regulatory Authority  
SAD  Single Ascending Dose  
SAP Statistical Analysis Plan  
SAE  Serious Adverse Event  
SD Standard Deviation  
SH-SY-5Y Human Derived Cell Line  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 7 of 57 SILK ™ Stable Isotope Labeling and Kinetics  
SNCAa53t Synuclein alpha  
SNRI  Selective Norepi[INVESTIGATOR_458818] / System organ class  
SSRI  Selective Serotonin Reuptake Inhibitor  
sTREM  Soluble Triggering Receptor Expressed On Myeloid Cells  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction   
t1/2 Half-life 
tau Tau protein  
TEAE  Treatment Emergent Adverse Event  
Tmax  Time to peak drug concentration  
TMF  Trial Master File  
TDP -43 TAR DNA -binding Protein 43  
TG transgenic  
WAIS -IV Wech sler Adult Intelligence Scales, 4th edition  
WHO  World Health Organization  
  
  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 8 of 57 TABLE OF CONTENTS  
SPONSOR SIGNATURE [CONTACT_1783]:  ................................ ................................ ................................ ...2 
PRINCIPAL INVESTIGATOR [INVESTIGATOR_96874] : ................................ ................................ ..[ADDRESS_586231] AND 
STUDY PROCEDURES  ................................ ................................ ............................ 23 
5.1. Risks and Benefits Associated with Buntanetap or Placebo  ................................ .......23 
5.2. Risk/Benefit Associated with Blood Collections  ................................ ........................ 24 
6.0 SAMPLE SI ZE AND STATISTICAL PLAN  ................................ ............................ 24 
6.1. Randomization  ................................ ................................ ................................ ............ 24 
6.2. Power and Sample Size Determination  ................................ ................................ .......24 
6.3. Safety and Tolerability Analysis  ................................ ................................ ................. 24 
6.4. PK Analysis ................................ ................................ ................................ ................. 25 
6.5. Criteria for Termination of the Trial  ................................ ................................ ........... 25 
6.6. Statistical Analysis  ................................ ................................ ................................ ......25 
6.7. Study Participants and Demographics  ................................ ................................ ........ 27 
6.7.1  Population Analys is Set  ................................ ................................ .............................. 27 
6.7.2  Disposition and Withdrawals  ................................ ................................ ...................... 27 
6.7.3  Protocol Deviations  ................................ ................................ ................................ .....27 
6.7.4  Demographics and Other Baseline Characteristics  ................................ ..................... 27 
6.7.5  Medical History and Concomitant Medications  ................................ ......................... 27 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 9 of 57 6.8 Analysis of Primary Endpoints  ................................ ................................ ................... 28 
6.9 Multiplicity Adjustment  ................................ ................................ .............................. 28 
6.10  Interim Analysis  ................................ ................................ ................................ .......... 29 
6.10.1   Re-estimation of Sample Size  ................................ ................................ .................... 29 
6.10.2  Communication of Int erim Results  ................................ ................................ ............. 30 
6.11  Safety and Tolerability Analyses  ................................ ................................ ................ 30 
6.12               Adverse Events  ................................ ................................ ................................ ........ 30 
6.12.1           Clinical Laboratory Evaluations  ................................ ................................ ............... 31 
6.12.2   Electrocardiogram (ECG)  ................................ ................................ .......................... 31 
6.12.3            Vital Signs  ................................ ................................ ................................ ................ 31 
6.12.4            Physical Examination Findings ................................ ................................ ................ 31 
6.12.5            Other Safety Parameters:  C-SSRS  ................................ ................................ .......... 31 
7 STUDY DRUG AND CONCOMITANT MEDICATIONS  ................................ ......32 
7.1 Identity of IP and Comparator  ................................ ................................ .................... 32 
7.2 Dosage  ................................ ................................ ................................ ......................... 32 
7.3 Packaging/Dispensing/Labeling  ................................ ................................ .................. 33 
7.4 Storage  ................................ ................................ ................................ ........................ 33 
7.5 Drug Accountability  ................................ ................................ ................................ ....33 
7.6 Compliance  ................................ ................................ ................................ ................. 33 
7.7 Breaking the Blind  ................................ ................................ ................................ ......34 
7.8 Concomitant Medications  ................................ ................................ ........................... 34 
7.8.1  Prohibited Concomitant Medications  ................................ ................................ .......... 34 
7.8.2  Permitted Concomitant Medications  ................................ ................................ ........... 34 
8 STUDY POPULATION  ................................ ................................ ............................. 35 
8.1              Inclusion Criteria  ................................ ................................ ................................ ......35 
8.2 Exclusion Criteria  ................................ ................................ ................................ .....37 
9 DESCRIPTION OF STUDY VISITS  ................................ ................................ ......... 40 
9.1 Screening Visit  ................................ ................................ ................................ ............ 40 
9.2 Baseline Visit  ................................ ................................ ................................ .............. 40 
9.3 Onsite Visit at 6 Weeks  ................................ ................................ ............................... 41 
9.4 12 Weeks Visit (End of Trial Visit)  ................................ ................................ ............ 42 
9.4.1  End of Trial Visit  ................................ ................................ ................................ ........ 42 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586232] End of Trial Visit 24 -Hour Phone Follow -up ................................ ..................... 43 
10 EARLY TREATMENT/STUDY DISCONTINUATION  ................................ .......... 44 
10.1  Reasons for Early Discontinuation  ................................ ................................ ............. 44 
11 STUDY -SPECIFIC INSTRUMENTS  ................................ ................................ ........ 45 
12 STUDY -SPECIFIC PROCEDURES  ................................ ................................ .......... 45 
12.1  Safety Assessments  ................................ ................................ ................................ .....45 
12.1.1  Physical and Neurological Examinat ion ................................ ................................ .....45 
12.1.2  Electrocardiogram (ECG)  ................................ ................................ ........................... 45 
12.1.3  Clinical Laboratory Evaluations  ................................ ................................ ................. 46 
12.2  Biofluids  ................................ ................................ ................................ ...................... 46 
12.2.1  Plasma for Biomarkers and Pharmacokinetics  ................................ ............................ 46 
13 PERSONNEL REQUIREMENTS  ................................ ................................ .............. 47 
14 ADVERSE EVENTS (AES)  ................................ ................................ ....................... 47 
14.1  Definition  ................................ ................................ ................................ .................... 47 
14.2  Following Up on AEs  ................................ ................................ ................................ .48 
15 SERIOUS ADVERSE EVENTS (SAE)  ................................ ................................ .....[ADDRESS_586233]  ................................ ....................... 49 
18 PRECAUTIONS/OVERDOSE  ................................ ................................ ................... [ADDRESS_586234] (DSMB)  ................................ .......50 
21 RECORDING AND COLLECTION OF DATA  ................................ ....................... 50 
21.1  Electronic Case Report Form (eCRF)  ................................ ................................ ......... [ADDRESS_586235] (IRB)  ................................ ................................ ............... 52 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586236] 
(HIPAA) Compliance  ................................ ................................ ................................ .[ADDRESS_586237] RETENTION  ................................ ................................ ............................. 53 
26 LITERATURE CITED  ................................ ................................ ............................... 54 
APPENDIX 1: SCHEDULE OF EVENTS  ................................ ................................ ................... 56 
 
 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 12 of 57 1.0 PROTOCOL SYNOPSIS  
PROTOCOL TITLE  A Randomized, Double -Blind, Placebo -Controlled, Dose -Ranging, 
Multicenter Study of Buntanetap in  Participants  with Mild to 
Moderate Alzheimer’s Disease  
STUDY DESIGN  The study will be a 12-week , placebo -controlled and double -blind: 
participants , investiga tors and the sponsor will be blinded to the 
participants ’ treatment.  
Qualified participants  will be randomly assigned at a 1:1:1 :1 ratio to 
one of the four treatment arms: buntanetap  7.[ADDRESS_586238] successfully completed the 
requisite certifications/trainings for each assessment .   All efforts will 
be made to ensure participants  will be assessed by [CONTACT_458843].   
One interim analysis is planned.  It will take pla ce when 90 enrolled 
participant s (~30%)  have completed the Week [ADDRESS_586239]  Buntanetap 7.5mg, 15 mg, 30mg,  or placebo  capsules , taken orally 
once a day for 12 weeks . 
SUMMARY OF KEY 
ELIGIBILITY 
CRITERIA   • Diagnosis of AD  
• Age 55 to 85  
• MMSE 14-[ADDRESS_586240]  
Aim 3.  MMSE  
EXPLORATORY 
OUTCOME MEASURES  Aim 1.  Plasma Biomarker s  
Aim 2.  Pharmacokinetics  
 
  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 13 of 57 2.0 INTRODUCTION  
Currently, there is no treatment available to stop or reverse the progression of Alzheimer’s 
(AD) and Parkinson’s disease  (PD) . Neurodegenerative diseases such as AD and PD share 
many common characteristics, including the central role of neurotoxic aggregating proteins 
in their pathogenesis. Amyloid β (Aβ) and tau aggregates (senile plaques and neurofibrillary 
tangles, respective ly) have been traditionally associated with AD, while α -synuclein (αSYN) 
aggregates (Lewy bodies) have been associated with PD. However, it is becoming 
increasingly clear that all these proteins are involved in both diseases and that aggregation 
of one can  lead to accumulation of another. Furthermore, in several studies of brains from 
older AD participants , a high percentage of all AD brains present mixed pathologies, such as 
Lewy body disease. Several clinical trials targeting just one (often Aβ) of the ne urotoxic 
aggregating proteins have failed. Finally, other fragments of Amyloid β Precursor Protein 
(APP) have been implicated in AD pathology.  Collectively,  these  facts  point  to the need  for 
lowering multiple neurotoxic aggregating proteins simultaneously,  if we are to have a good 
chance of at least halting disease progression.  
Buntanetap  has a unique mechanism of action, in that it inhibits the translation and, therefore, 
reduces the levels of several neurotoxic aggregating proteins both in vitro  and in vivo, including  
α-Synuclein (αSYN), Amyloid Precursor Protein (APP), its fragments, and tau. Although APP 
and its downstream products (Ab oligomers, c -terminus peptide, and amyloid plaques), and tau 
neurofibrillary tangles have been well documented to be cul prits of AD, recent research has 
shown that other misfolded proteins are also part of the equation. For example, increased levels 
of αSYN and TDP -[ADDRESS_586241] one.  
αSYN,  APP,  tau, and TDP43  contribute  to the progression  of AD and PD in similar  ways:  they 
impair  axonal  transport  and lower  neurotransmitter  and neurotrophic  factor  release,  they cause  
inflammation,  they form  aggregates,  and, finally,  they lead to nerve  cell death.  In our in vitro and 
in vivo preclinical  studies,  buntanetap  has normalized  all those  actions.  
Preclinical  data proves  buntanetap ’s efficacy  in restoring  memory  and learning  in an APP/PS1  tg 
mouse  model  of AD, restoring  axonal  transport  in DS trisomic  mice,  preserving  memory,  and 
learning  in traumatic  brain  injury  rats and in stroke  mice,  and preserving  the retina  in acute  
glaucoma . Bunt anetap  also restores  colonic  motility  in a human  SNCAA53T transgenic  (tg) mouse  
model  of early  PD.  
Buntanetap’s  safety  has been  established  in three  Phase  1 clinical  studies  by [CONTACT_458844] 
(2012) . Importantly,  buntanetap  normalized  levels  of APP,  tau and αSYN,  as well as 
inflammatory  markers  in the cerebrospi[INVESTIGATOR_155456]  (CSF)  of mildly  cognitively  impaired  (MCI)  
participants  at a dose of 4x60  mg/day  (Protocol  QR12001).   
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 14 of 57 Recen tly, we also tested  buntanetap  in the DISCOVER  study  at 1x60,  2x60  and 3x60  mg/day  for 
up to 25 days to see if it changes  the synthesis  and degradation  kinetics  of Aβ in a stable  isotope  
labelling  kinetic  (SILK)  study.   The DISCOVER  study  is conducted  by [CONTACT_458845] 16 treated  participants  (Protocol  QR1500 1). The study  officially  finished  in 
December  2021,  with 7 patients  treated  in cohort  1 (1x60mg/day),  6 patients  in cohort  2 
(2x60mg/day),  and 2 patients  in cohort  3 (3x60mg/day).  The CSF measurements  of Aβ showed  
in a dose-dependent  fashion  that buntanetap  slows  the synthesis  and lowers  the total amount  of 
Aβ synthesized  by [CONTACT_2016]. It also showed  improvement  in cognition  as measured  by [CONTACT_458846] -
Cog11  scale.  
We recently completed  a double Phase  2a study (ANVS -[ZIP_CODE]) in both early AD and  early  PD 
populations.  In AD, 14 participants  were recruited and randomized into 80mg QD buntanetap or 
placebo for 25±2 days. CSF biomarker results show that buntanetap lowered multiple neurotoxic 
proteins levels (sAPPa, sAPPb, t otal Tau, phosphorylated Tau), reduced inflammation (shown by 
[CONTACT_458847], YKL -40, sTREM and Complement C3), preserved axonal integrity shown by 
[CONTACT_458848] (NFL) and improved synaptic density shown by [CONTACT_458849] (NG). 
Buntanetap also improved AD partici pants  ADAS -Cog 11 score as well as WAIS coding score  
(Fang 2022 ). 
In PD, 54 participants  were recruited and randomized into 0, 5, 10, 20, 40 and 80mg QD 
buntanetap  for 25±2 days. CSF biomarkers were collected and analyzed. MDS -UPDRS and 
WAIS coding were te sted. CSF biomarker results show that buntanetap  lowered αSYN  level, 
reduced inflammation (shown by [CONTACT_458847], YKL -40, sTREM and Complement C3), preserved 
axonal integrity shown by [CONTACT_458850]. Although sample 
size was not powe red to see efficacy, buntanetap  impro ved PD participants  WAIS coding scores 
at all doses including 5mg QD. Buntanetap also improved PD participants  MDS -UPDRS Part III, 
IV and Total score  (Fang 2022 ).  
In this study, we want to confirm buntanetap ’s efficacy in a diverse population of mild to 
moderate  AD participants . We only tested 80mg QD in our Phase2a study in AD participants . 
During the dose -finding Phase  2a PD study, we saw a dose -response curve bet ween 0 and 10/[ADDRESS_586242] the efficacy of 7.5 mg, 15mg 
and 30 mg QD  buntanetap .  
2.1. OBJECTIVES  
Study objectives include assessing buntanetap ’ s efficacy  and safety  in participants  with mild to 
moderate AD .   
Study drugs will be 7.5 mg, 15mg, 30mg  of buntanetap , or matching placebo  capsules , taken 
once per day in the morning  right before food . Eligible  participants  will be randomly assigned at 
a 1:1:1 :1 ratio to one of the four treatment arms: buntanetap  7.[ADDRESS_586243] successfully 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 15 of 57 completed the requisite certifications/trainings for each assessment . All efforts will be made to 
ensure participants  will be assessed by [CONTACT_458851].   
  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 16 of 57 2.2. ENDPOINTS  
Primary Endpoints:  
1. ADAS -Cog11  
Change  in Alzheimer ’s Disease Assessment Scale -Cognitive Subscale 11 ( ADAS -Cog 11 ) 
from baseline to the end of treatment period  (12 weeks ). ADAS -Cog 11  measures cognitive 
functions and non -cognitive functions such as mood and beh avior. Total scores range from 0 -
70, with higher scores indicating greater cognitive impairment.   
2. Alzheimer ’s Disease Cooperative Study -Clinical Global Impression of Change (ADCS -
CGIC)   
ADCS -CGIC is a validated categorical measure of change in the participant ’s clinical 
condition between baseline and follow -up visits. It measures whether the effects of active 
treatment are substantial enough to be detected by a skilled and experienced cli nician on the 
basis of a clinical interview and examination. It relies on both direct examination of the 
participant  and an interview of the study partner. A skilled and experienced clinician who is 
blinded to treatment assignment rates the participant  on a 7-point Likert scale, ranging from 1 
(marked improvement) to 7 (marked worsening). Lower scores indicate better improvement.  
 
Secondar y Endpoints:  
1. Alzheimer ’s Disease Cooperative Study -Instrumental Activities of Daily Living Scale 
(ADCS -ADL ) 
The ADCS -ADL  is a 23-item inventory  developed  as a rater-administered  questionnaire  
answered  by [CONTACT_2299] ‘s study  partner . The ADCS -ADL  measures  both basic  and 
instrumental  activities  (instrumental  activity  items  6a, 7-23) of daily  living  by [CONTACT_458852] a lower  score  indicating  greater  severity.  
2. Mini Mental State Examination (MMSE) Score  
MMSE is a brief screening instrument used to assess cognitive function (orientation, 
memory, attention, ability to name [CONTACT_272755], follow verbal/written commands, write a 
sentence, and copy figures). Total score ranges from [ADDRESS_586244] (DSST)  
In the digital symbol substitution  test (DSST)  individuals are asked to record as sociations 
between different symbols and numbers within time limits . The total score is the sum of all 
the correctly coded numbers and higher score s indicate better performance . 
Exploratory Endpoints:  
1. Plasma biomarker s 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 17 of 57 Potential biomarkers to be measured in plasma are A42/40 ratio, pTau 181, pTau217, 
Neurofilament Light (N FL), Glial fibrillary acidic protein ( GFAP ), TDP43 . 
 
2. Pharmacokinetics  
The following PK parameters will be determined: Area under the curve (AUC), Cmax,  
Tmax, t½, and CL.  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 18 of 57 3.0 COMPLETED STUDIES  
The f ollowing is a summary  of the available  information on buntanetap . Detailed information  
can be found in the current buntanetap  Investigational Drug Brochure.  
3.1. Summary of Non -Clinical Findings  
In APP transgenic AD mice, buntanetap  led to a decrease in APP levels, improved neuronal stem 
cell survival and increased levels of brain-derived neurotrophic factor  (BDNF ) (Marutle 2007 , 
Kadir 2008 , Lilja 2013 ). Chronic administration of buntanetap  to APP transgenic mice totally 
prevented decline in memory and learning as well as in long -term potentiation at brain and 
plasma concentrations that are 10 times lower than originally published  (Teich 2018 ). In alpha -
synuclein  (αSYN) transgenic PD mice, buntanetap  restored gut motility to normal and lowered 
aSYN in the brain and gut of the tg PD mice. Again,  the efficacious levels were 10 times lower 
than originally published (Kuo 2019 ). In DS trisomic mice buntanetap  fully restored axonal 
transport in vitro  and in vivo  (Chen 202 0). In summary, buntanetap  is a translational inhibitor of 
APP and aSYN and fully restores function at doses that are very low and very safe, and the 
plasma levels seen are attainable  with low oral dosing in humans . 
Buntanetap  was not mutagenic or clastogenic as assessed by [CONTACT_397761].  
The cardiac electrophysiological properties of buntanetap  tartrate were negative in vitro  using 
human ether -a-go-go related gene  (hERG ) transfected human embryonic kidney cells (HEK 
293). Buntanetap  did not adversely af fect the interval seen in an electrocardiogram (E CG) test 
(QT (or QTc) ) interval.   
Four -week t oxicity studies in dogs showed b rain toxicity (ataxia and tremors/twitching) and 
gastrointestinal ( GI) toxicity at 30 mg/kg/day, which was dose -dependent and reversible. The no 
observed adverse effect level  (NOAEL ) was 20 mg/kg/day in dogs. The signs/symptoms noted at 
high doses of bunta netap  may be related to cholinergic manifestations. In in vitro  assays, 
buntanetap  showed minimal inhibition of AChE  or BChE (Butyrylcholinesterase) activity, 
however, a metabolic product of buntanetap , N1-norposiphen demonstrated acetyl cholinesterase 
inhibitory activity ( Yu 2013 ). There were no effects on the reproductive organs associated with 
4-week exposure to buntanetap  in male or female rats or dogs.  
Repeat Oral dose Toxicity Study of  buntanetap  in male and female rats giving 10, 2 0 and 40 
mg/kg for 26 week s showed that N OAEL dose was 40  mg/kg for both male and female rats. 
Repeat Oral dose Toxicity Study of buntanetap  in male and female dogs giving 5, 10 and 20 
mg/kg for 39 weeks showed that NOAEL dose was 20  mg/kg for both male an d female dogs.   
3.2. Summary of Clinical Findings  
Three Phase  [ADDRESS_586245] was a single ascending dose ( SAD ) study in healthy volunteers; 
the second was a multiple ascending dose (MAD ) study in healthy volunteers , and the third one 
was a pharmacokinetic ( PK)/pharmacodynamic  study of CSF in mild cognitively impaired 
participant s (Protocol QR12001) . One Phase1/2 study (Discover) was to test the safety, 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 19 of 57 tolerability, PK and PD of  buntanetap in subjects with early Alzheimer's disease  (Protocol 
QR12005). The other  Phase  2a study was a double study for both early AD and early PD 
participants  to test buntanet ap’s safety , pharmacokinetics, biomarkers , and efficacy  (Protocol 
ANVS -[ZIP_CODE] ). 
In the SAD trial, buntanetap  was administered orally in doses of 10, 20, 40, 80, and 160 mg. 
Limiting side effects observed following the 160 mg dose resulted in curtailmen t of the study 
without administration of the 320 mg dose.  The 160 mg dose was associated with an increased 
incidence of nausea and vomiting (four participants  were nauseous and three vomited). Adverse 
events were either mild or moderate; none were severe. Buntanetap  [ADDRESS_586246] level . 
Following oral administration, peak concentration was achieved rapi[INVESTIGATOR_375], with mean obs erved 
Tmax between 1.3 and 1.6  hours for both males and females at all doses. C max increased with 
increasing dose, as did the various measures of AUC. Differences in mean observed C max and 
AUC between males and females at each dose appeared to be related t o body weight rather than 
gender differences.  
In the MAD  trial, buntanetap  was administered orally in doses of 20, 40, and 60 mg 4 times a 
day ( QID). The first two treatments were dosed  for [ADDRESS_586247] day to determine the pharmacokinetics of the drug. In 
general , the drug was well tolerated, resulting in no serious or severe adverse events and only 
one premature disco ntinuation, a participant  in the 60  mg group discharged because of nausea, 
vomiting, dizziness and “feeling warm .” The incidence of adverse events, all either mild or 
moderate severity , also occurred with similar frequency in the placebo group. The most common 
AEs were dizziness, headache, and nausea/vomiting.  
Buntanetap  was absorbed rapi[INVESTIGATOR_279159], achieving maximum plasma and CSF 
concentration ( Cmax) within 1.2 -1.5 hours. For the 40 and 60 mg doses, with fully defined plasma 
profiles, the mean terminal t ½’s were 3.80 ±0.88 and 5.23±1.[ADDRESS_586248] ively after a single 
dose and 3.53±1.03 and 4.104±0.91 hours, respectively, after repeat dosing. The half-life ( t½) of 
the plasma concentrations at the lower doses could not be calculated accurately. The C max 
increased with dose (24, 144, and 2310 ng.h/mL after a single dose of 20, 40, and 60 mg, 
respectively and 110, 134, and 2101 ng.h/mL after multiple doses of 20, 40, and 60 mg, 
respectively).  
In the proof of mechanism of action study  (Protocol QR12001) , the PK of buntanetap  was 
measured after 10 days of administration (4x60 mg) over [ADDRESS_586249] dose at day 11 of buntanetap  administration.  We 
found that the plasma concentrations of buntanetap  overlapped with the plasma concentrations 
found in the MAD study. In this study, the N1 -metabolite reach ed about 10 to 15%, while the 
level of the N8 -metabolite reach ed about 20 to 25% of the buntanetap  levels measured in plasma.  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586250] the cholinomimetic properties of molecules in this 
class, buntanetap ’s highest tolerated dose is determined by [CONTACT_458853] N 1-metabolite  in 
blood and brain.  
While the t1/2 of buntanetap  in plasma was 4-5 hours as seen in the SAD and MAD studies, the 
t1/2 in CSF/brain was longer than [ADDRESS_586251].  
For the Phase 2a trial  (Protocol ANVS -[ZIP_CODE]) , there are two parts of the study. In part one, early 
AD participants  were given 80  mg QD buntanetap  or placebo for 25 days.  In the second part, 
early PD participants  were given 5  mg, 10  mg, 20  mg, 40  mg, 80mg  QD buntanetap  or placebo 
for 25 days. In all doses and in both AD and PD participants , buntanetap  was safe and well 
tolerated. No SAE was reported.  
Buntanetap  was absorbed rapi[INVESTIGATOR_279159], achieving maximum plasma and CSF 
concentration (C max) within 1-2 hours. For the 80 mg doses, with fully defined plasma profiles, 
the mean terminal t ½’s were 2.76 ± 2.668  hours . The half -life (t ½) of the plasma concentrations at 
the lower doses  (5 & 10  mg) could not be calculated accurately. The C max increased with d ose 
(15.31 , 40.19 and 112.31  ng.h/mL after a single dose of  20, 40 and 80 mg, respectively ). 
Consistent with Phase  1 POC study, 80mg QD buntanetap  reduced AD participants ’ CSF levels 
of sAPP, sAPP, total tau, phosphorylated tau (tau181),  αSYN and a series of inflammatory 
markers  (YKL -40, GFAP, sTREM2 , Complement C3). Buntanetap also impro ved axonal 
integrity shown by [CONTACT_458854] (NFL) and synaptic function shown by [CONTACT_458849] 
(NG). Similarly, 80  mg QD  buntanetap  reduced PD participants ’ CSF levels of αSYN and a 
series of inflammatory markers  (YKL -40, GFAP, sTREM2, Complement C3). Buntanetap also 
improved PD participants ’ axonal integrity shown by [CONTACT_458855].  
Further, buntanetap  treatment improved AD participants ’ cognition shown by [CONTACT_33341] -Cog11 and 
WAIS coding test and improved PD participants ’ movement shown by [CONTACT_274657] -UPDRS and WAIS 
coding test  in our Phase2a studies . 
  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 21 of 57 4.0 BACKGROUND AND STUDY RATIONALE  
4.1. Background  
Although APP and its downstream products (A β oligomers, c -terminus peptide, and amyloid 
plaques), and tau neurofibrillary tangles have been well documented to be culprits of AD, recent 
resea rch has shown that other misfolded proteins are also part of the equation. In AD, in addition 
to Aβ and tau, increased levels of αSYN and TDP -[ADDRESS_586252] been shown to be correlated with 
deficits in cognitive functions . A high load of inflammation and microgli a activating factors that 
contribute to neurodegeneration  are also common in AD. 
Buntanetap  (Posiphen)  is the (+) enantiomer of phenserine , but while phenserine inhibits AChE , 
buntanetap  has no AChE  activity itself and develops some activity in vivo with the metabolism 
to N1 -bisnorposiphen. In vivo , phenserine has about 10-20 times more AChE  inhibitory  activity  
than buntanetap ’s metabolite N1 -bisnorposiphen.  
Buntanetap  has been found to significantl y reduce soluble APP and A β as well as tau, p -tau and 
αSYN  in the rodent brain and  in human CSF. In preliminary studies in animals and humans , 
inhibition of APP, A β, tau, p -tau and αSYN  occurs at levels 8 to 16 times lower than the levels 
causing cholinomimetic effects.  
Buntanetap  acts at the 5’UTR of the  aSYN and  APP mRNA and lowers their protein expression 
levels in animal models ; it decreased sAPP α and β, tau, p -tau and aSYN  levels in human CSF. 
Our data suggests that these effects are achieved via the same mechanism : the 5’UTR s of these 
mRNAs form a complex with iron regulatory protein [ADDRESS_586253] in AD, PD as well as other neurodegenerative 
disorders.  
4.2. Study Overview  
Study population:  The study will be conducted in a diverse population of participants  with mild 
to moderate  AD. 
Dose selection : Qualified participants  will be randomly assigned at a 1:1:1 :1 ratio to one of the 
four treatment arms: buntanetap  7.5 mg, buntanetap  15 mg, buntanetap 30mg,  and placebo .  
Study Design:  [ADDRESS_586254]-time dosing in clinic , followed by [CONTACT_458856] e dosing period of 12 weeks , with  daily  
administration of  7.5 mg, 15 mg , or 30 mg of buntanetap  or placebo .  Participants will  be 
required to  visit clinics  Day 0 (baseline) , 6 weeks , and 12 weeks  (end-of-trial), where the y will 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 22 of 57 undergo study procedures that include safety assessments (AE and concomitant medication 
monitoring, 12 -lead ECGs, clinical laboratory testing, vital signs assessments, and 
physical /neurological  examinations)  and psychometric tests ( ADAS -Cog11, ADCS -CGIC, 
ADCS -ADL , DSST , MMSE ). At the end of blood sampling, the participants  will need to stay for 
a minimum of 1 hour of observation . After all  end-of-study procedures are complete , the 
participant  will be discharged to home.  A 24 -hour follow -up call  will occur after all clinical 
visits to assess the participants current condition and if there are any additional adverse events or 
questions .   
Participants  who drop out during the initial 9 weeks at h ome treatment period will be 
discontinued and complete a n early discontinuation  visit as soon as possible following 
discontinuation .  Participants  that drop out after the initial 9 weeks  will be scheduled for an end 
of trial visit.  If 4 participants  are d iscontinued due to severe adverse events a DSMB safety 
review will be conducted without interrupting the study.  
4.3. Outcome Measures  
Efficacy outcome measures: Buntanetap has shown to improve AD participants ’ cognition . 
ADAS -Cog 11 and MMSE will be measured to assess its improvement on AD participants ’ 
cognition, ADCS -ADL  will be measured to assess its improvement on AD participants  daily 
living functions . ADCS -CGIC  will also be measured to assess its effect  in AD partici pants ’ 
performance. DSST will be measured to assess AD participant ’s CNS dysfunction.  
Safety outcome measures: Reports of adverse events ( AEs) and serious adverse events ( SAE s) 
during exposure to buntanetap  will be collected  to evaluate if there are any significant clinical 
safety issu es for  the study population. Extensive clinical and laboratory safety data already exist 
for buntanetap ; therefore , these safety measures  will be sufficient in the proposed study.  
Clinical , functional  and cognitive asses sment measures:  The participants  will be administered 
the MMSE (Folstein  1975 ) for determination of inclusion into the study. The ADAS -Cog11  
(Rosen 1984)  and MMSE  will be administered for participants ’ cognitive  function .  The ADCS -
ADL  (Galasko 1997 ) will be administered for participants ’ daily activity. ADCS -CGIC  (Guy 
1976)  will be administered for participants  cognitive and daily functions.   The DSST  (WAIS -IV; 
Wechsler 2008 ) will serve as a sensitive measure of CNS dysfunction.   
Exploratory measures : Buntanetap has shown to reduce neurotoxic proteins, reduce 
inflammation and preserve axonal integrity and synaptic functions in previous Phase 2a studies. 
In this study we potentially plan to measure plasma A42/42 ratio , GFAP, NFL, p -Tau 181, p -
Tau21 7 and TDP43.  
  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586255] pla cebo (inactive ingredients) will be provided. The placebo used for the 
study consists of standard (non -lactose) pharmaceutical excipi[INVESTIGATOR_458819] (GRAS), with no known side effects anticipated . 
Buntanetap has been tested in a nimal safety studies. No adverse effects were observed in rats 
given doses up to 40 mg/kg/day for 26 weeks. Drug -related effects observed in dogs included 
severe tremors at ≥20 mg/kg/day, ataxia , and gastrointestinal erosion/ulcer/inflammation at ≥30 
mg/kg /day, convulsions at ≥60 mg/kg/day, and duodenal necrosis and death at 100 mg/kg 
(equivalent to a human dose of 3,350 mg).  No adverse effects were observed in dogs  given doses 
up to 20 mg/kg/day for 36 weeks . 
In clinical studies to  date, buntanetap  has bee n well tolerated with single doses o f 80 mg or  less 
and QID doses of 60 mg  up to 25 days . A higher  single dose of 160 mg was associated with an 
increased incidence of nausea and vomiting . Aside from nausea and vomiting, which are well -
known responses to treatment  with AChE  inhibitors, the only consistent pattern of AEs entailed 
dizziness/fainting, head ache, and reduction in total serum protein. These effects w ere seen to 
varying degrees at all doses of buntanetap  and in the placebo group. The re was a tendency, but 
no definitive pattern of increased incidence of A Es with increasing dose of buntanetap . There 
have been no  SAEs in prior clinical studies with buntanetap . 
Definitive reproductive and developmental toxicity studies have not been condu cted with 
buntanetap . As a result,  women of childbearing potential will be excluded from participati ng in 
this study  unless they agree to be on contraceptive for the whole duration of the trial and  four 
weeks after. Female partners of male participants of childbearing potentials will also need to 
agree to be on contraceptive for the whole duration of the trial plus an a dditional four weeks .  
Male study participants should not donate sperm and female study participants should not donate 
eggs during the whole duration of the trial and four weeks after .  
At this time, there is no controlled clinical data available for anyon e receiving SARS -CoV -2 
(COVID19) vaccination while being treated with buntanetap. However, based on the intended 
mechanism of actions and currently available data for these vaccine candidates and for 
buntanetap, it is not believed that there are specific r isks to consider in participants  participating 
in this study who have received SARS -CoV -2 (COVID19) vaccination or who are planning to 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 24 of 57 receive the vaccination. As such, SARS -CoV -2 (COVID19) vaccination is not prohibited. If 
appropriate, SARS -CoV -2 (COVID19 ) vaccination should be considered as a concomitant 
medication.  
5.2. Risk/Benefit Associated with Blood Collections  
Phlebotomy is associated with mild to moderate discomfort due to pi[INVESTIGATOR_458820]. This can 
be minimized with the use of a well -trained phleb otomist/nurse. Sometimes the blood draw site 
may become discolored with a “bruised” appearance that is transient and not painful. Rarely, the 
blood draw site may become infected and require antibiotic treatment.  
6.0 SAMPLE SIZE AND STATISTICAL PLAN  
A sample si ze of up to 320 participants  (1:1:1 :1 randomized to 7.5mg, 15mg, 30mg  buntanetap  
and placebo respectively) is planned  to be randomized .  
Definitions of the analys is populations  and a detailed description of the analysis rules will be 
presented in a separate  Statistical Analysis Plan (SAP).  
6.1. Randomization  
Participants  who have signed an informed consent and meet screening eligibility requirements 
will be randomly assigned  to the active and placebo treatment groups at 1:1:1 :1 ratio.  The 
randomization methodology used is permuted block randomization . 
6.2. Power and Sample Size Determinatio n 
Qualified participants  will be randomized at a 1:1:1:1 ratio to one of the following three 
treatme nt groups: 7.5 mg, 15 mg, 30 mg QD buntanetap and placebo. A sample size of 280 (210 
combining all three buntanetap -treatment groups and 70 in control) will have a 90% power to 
detect a treatment difference for the primary efficacy variable ADAS -Cog11 at a  two-sided 
significance level of 0.05, assuming a delta of 2.7 between the treatment (pooling all three 
treatment arms together) and placebo, and a common standard deviation of 6.0.  This sample size 
will also have a n 89% power to detect a significant diff erence for the co-primary  efficacy 
variable ADCS -CGIC at a two -sided significance level of 0 .05, assuming a delta difference 0. 23  
between the treatment (pooling all three treatment arms together) and placebo,  and a common 
standard deviation of 0.5. Appro ximately 320 participants  will be randomized (approximately 80 
per arm) to account for an expected 12.5% dropout rate.  
6.3. Safety and Tolerability Analysis  
Safety and tolerability will be assessed with physical examinations, vital signs, clinical 
laboratory values, 12-lead ECG, use of concomitan t medications, and AE reports. The 
frequencies of adverse events, serious adverse events,  and laboratory abnormalities between the 
participants across the treatme nt groups  will be compared .  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 25 of 57 Participants  who dropout during the initial 9 weeks  at-home treatment period will be 
discontinued  and invited to an Early Discontinuation visit . Participants  that drop out after the 
initial 9 weeks  will be scheduled for an end -of-trial visit. If 4 participants  are discontinued due to 
serious adverse events a DSMB safety review will be conducted without interrupting the study .   
6.4. PK Analysis  
Plasma concentration -time data will be analyzed  by [CONTACT_105]-compartmental methods using SAS 
version 9.4 or greater.  Calculations  will be based on the actual sampling  times  recorded during  
the study. Since the study is blinded , all participants ’ plasma will be included in the  PK 
analysis . From the plasma  concentration -time data, the  following  PK parameters will minimally 
be determined, as data  permit: Area under the curve ( AUC ), Cmax, Tmax, t½, and CL . Dose -
proportionality  may be calculated  on Cmax  and AUC  as appropriate . 
Plasm a concentration -time data for buntanetap  will be listed and summarized descriptively  
(number of  participants  (N), mean, median, standard deviation (SD), minimum (min), and 
maximum (max))  and graphically  presented.  PK parameters will be listed and summarized 
descriptively  (N, mean,  median, SD, min, max, and 95% CI) by [CONTACT_458857].  In addition, 
geometric means,  and between -participant  coefficients of variation (CV)  will be  calculated . 
6.5. Criteria for Termination of the Trial  
The trial may be terminated by [CONTACT_458858], and Data Safety 
Monitoring Board ( DSMB ) recommendations.  
An independent Data Monitoring Board ( DSMB or IDMB) will be formed to safeguard the 
participants ’ wellbeing. The responsibilities  of IDMB will be established in the IDMB Charter. 
The study will have a safety  analysis when 90 randomized participants  (about 30% of the 
targeted sample size) have been treated for 6 weeks.   
6.6. Statistical Analysis  
Continuous variables will be summarized usi ng the following descriptive statistics: number of 
subjects, mean, median, standard deviation (SD), standard error (SE), minimum, and maximum. 
Unless otherwise specified, means, medians and confidence intervals (CIs) will be presented to 
one more decimal p lace than the raw data, and the SD and SE will be presented to two more 
decimals than the raw data. In general, the maximum number of decimal places is 4. Wherever 
possible, data will be decimally  aligned.  
Categorical variables will be summarized by [CONTACT_941] n umber of subjects and the percentage  of 
subjects in each category. Categories with zero counts will not have zero percentages displayed. 
For demographic summaries, percentages will be calculated by [CONTACT_458859]. Percentages will be presented with one decimal 
place.   
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 26 of 57 Unless otherwise specified, all statistical tests will be 2 -sided at the significance level of 5% and 
all the Cis will be 2 -sided 95%. P -values will generally be presented to 4 decimal places; values 
less than 0.0001 will be presented as <0.0001.  
 
  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 27 of 57 6.7. Study  Participants  and Demographics  
6.7.1 Population Analysis Set  
Enrolled Analysis Set: The enrolled population will include all participants who signed Informed 
Consent and meet all inclusion and exclusion criteria.  
Randomized Analysis Set: The Randomized Analysis Set (RAS) consists of all participants  who 
were randomized. Subjects will be classified according to the randomized treatment assignments.  
Safety Analysis Set: The Safety  Analysis Set ( SAS) consists of all randomized participants who 
received at least one  dose of study drug . Subjects will be analyzed  according to the actual  
treatment.  
Full Analysis Set: The Full Analysis Set ( FAS) consists of all participants  who were randomized , 
received at least one dose of study drug, and have both a baseline and at lea st one post -baseline 
value for the ADAS -Cog11  or ADCS -CGIC score after taking study drug . Subjects will be 
analyzed  according to the treatment they were randomized.  
Per Protocol Analysis Set:  The Per-protocol Analysis Set consists of all participants in the FAS 
who do not have major protocol deviation. The membership of this analysis set will be 
determined prior to database lock.  
6.7.2 Disposition and Withdrawals  
The numbers of participants  screened, randomized, completing,  discontinuing treatment,  and 
withdrawing, along with reasons for  discontinuation or  withdrawal, will be tabulated overall and 
by [CONTACT_1570]. The number of participants  in each analysis population will be reported.  
6.7.3 Protocol Deviations  
Major protocol d eviations will be classified and documented  before database lock  and will be 
discussed in the CSR . All protocol deviations, both minors and majors, will be presented in a data 
listing.  
6.7.4 Demographics and Other Baseline Characteristics  
Demographic and baselin e characteristics (including age, sex, race /ethnicity , weight, and height) 
will be summarized for each treatment group and for the overall population by [CONTACT_84814].  
6.7.5  Medical History and Concomitant Medications  
Medical history will be listed.  Prior and concomitant medications will be summarized by [CONTACT_6490], by [CONTACT_458860], classified using 
World Health Organization (WHO) Drug Dictionary Anatomical Therapeutic Chemical  (ATC)  
classes and p referred terms.  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 28 of 57 6.8 Analysis of Primary Endpoint s 
The co -primary endpoints are the change from baseline to 12 weeks in ADAS -Cog11 scores and 
the ADCS -CGIC scores at 12 weeks. The ADAS -Cog11 will be analyzed via mixed models for 
repeated measures (MMRM). The mo del for ADA S-Cog11 will include treatment, timepoint, 
treatment -by-timepoint interaction as the fixed effects , baseline ADAS -Cog11as the covariate ,  
and subjects as random effect. The Model for ADCS -CGIC will include treatment, timepoint, 
treatment -by-timepoint interaction as the fixed effects  ,  and subjects as random effect. An 
unstructured covariance matrix  will be used and the Kenward -Roger approximation will be used 
to adjust the denominator degrees o f freedom . The change from baseline and the differences in 
the change from baseline between treatments will be based on the Least Square Means from this 
model. The two -sided 95% confidence intervals of the treatment differences will be presented . 
6.9 Multiplic ity Adjustment  
The primary study hypothesis is that, the buntanetap -treatment (pooling three treatment arms 
together) is superior to placebo in reducing the cognitive impairment of AD patients, as assessed 
by [CONTACT_458861] -primary endpoints: change from basel ine in the ADAS -Cog11  score at 12 -weeks 
and ADCS -CGIC score at 12 -weeks. The two co -primary endpoints will be tested at a two -sided 
significance level of 5% without multiplicity adjustment. If both test hypotheses are rejected at 
the 5% level, the test wil l continue onto secondary endpoints in a gatekeepi[INVESTIGATOR_458821], 
at a two -sided significance level of 5%.  
The study is also designed to explore the effectiveness of three buntanetap -treatment  dose level. 
Nominal p -values will be provided for these t est hypotheses of each dose arm vs. placebo, 
without multiplicity adjustment.  
  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 29 of 57 6.10 Interim Analysis  
An interim sample size re -estimation  will be performed after a total of 𝑛1 = [ADDRESS_586256] baseline and  Week 6 values  of one or both co -
primary efficacy endpoints. The aim of the interim sample size review is to re -assess the size of 
the estimated mean difference between the treatment (pooling three treatment arms together) and 
placebo, and standard deviati ons of the co -primary endpoints ADAS -Cog11 and ADCS -CGIC to 
ensure sufficient power at the final analyses.  
No Interim analyses are planned for the purpose of stoppi[INVESTIGATOR_458822].  
6.10.1   Re-estimation of Sample Size  
The initial planned sample size was determined for ADAS -Cog11 based on a targeted power of 
90% to detect a delta of 2.7 between the treatment (pooling three arms together) and placebo, 
with a common standard deviation of 6.0 at a two -sided significance lev el alpha of 5%.  This 
sample size will also have a power of 89% to detect a significant difference for the co -primary 
effectiveness variable ADCS -CGIC at a two -sided significance level of 5%, assuming a delta of 
0.[ADDRESS_586257] deviation of 0.5 . Accounting for an expected drop -out rate of 
12.5%, a sample size of approximately 320 participants (80 per treatment arm) was calculated to 
achieve 280 evaluable participants (70 per treatment arm).  
To guarantee sufficient power for the primary trial ob jectives, sample size will be re -estimated 
based on the calculated conditional power at the interim analyses. The conditional power for 
each co -primary endpoint will be calculated at the significance level of 0.05 separately, 
according to the methodology a nd equation from Mehta and Pocock (2011) . The sample size will 
only be increased if the conditional powers for both co -primary endpoints are >50% (and <90%), 
otherwise, the trial will continue as planned, i.e., no decrease in sample size or stoppi[INVESTIGATOR_458823]. The target power is 90% and 
maximum sample size per group is set to be 100 participants per arm. Specifically, if both 
conditional powers at interim analysis are >50%, then each arm will b e increased to 100 
participants. Otherwise, the trial will continue as is.  
Chen, Lan and Demets (2004) have shown that, when conditional power >=50%, one may 
increase sample size to 𝑛2∗ and the conventional test statistics and critical values can be used  at 
the final analysis, the overall type I error rate will not be inflated. Further, Chen, Yuan and Li 
(2018)  demonstrated that the conventional maximum likelihood estimate,  and coverage error of 
its conventional confidence interval are generally small fol lowing sample size adjustment. 
Therefore, conventional point estimate and confidence interval are recommended to be used 
when applying the 50% conditional power principle for sample size re -estimation, to keep 
consistent statistics in both hypothesis test and statistical inference.  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586258] access to blinded aggregated ADAS -Cog11 and ADCS -CGIC results (pooled trial data) for 
the purpose of data review and will have no other responsibilities associated within the study. 
These results will be provided by [CONTACT_458862].   
 
6.11 Safety  and Tolerability Analyses  
All safety  summary  analyses will be performed using the actual treatment for the Safety Analysis 
by [CONTACT_458863] -treatment  group.  
Safety and tolerability will be assessed through TEAEs; hematologic, biochemical, and 
urinalysis laboratory parameters; physical examination findings; and vital signs measurements.  
No formal statistical comparisons will be performed for safety endpoints.  
6.12               Adverse Events  
Adverse events (AEs) will be coded using MedDRA dictionary, Version 25.1 or newer.  
An AE will be considered as a treatment -emergent AE (TEAE) if started after first do se and no 
later than last dose date + [ADDRESS_586259] 
dose.  
The event counts, number and percentage of subjects reporting TEAEs in each treatment group 
will be tabulated by [CONTACT_9313] (SOC) and preferred term (PT); by [CONTACT_2946], PT and 
maximum severity ; by [CONTACT_2946], PT and relationship to study drug and by [CONTACT_458864] (within treatment group). If more than one TEAE occurs with the same PT for the same 
subject, then the subject will be counted only once for that preferred term using the most se vere 
and most related occurrence for the summary. The display in these tables will be sorted 
alphabetically by [CONTACT_458865] (within treatment group) within 
each SOC.  
The incidence of most frequently reported (PT frequency >=5 % in any group) TEAEs, SAEs 
reported after treatment start, TEAEs leading to drug withdrawn, and TEAEs related to study 
drug will be summarized by [CONTACT_3592].  
An AE listing by [CONTACT_458866], and will include the verbatim term in addition to 
the MedDRA SOC and PT. This listing will also include all relevant eCRF data associated with 
the event: date of onset, date resolved, date of last dose, sev erity, frequency, outcome and 
relationship to study drug and action taken with study drug. Separate listings will be presented 
for subjects with treatment -emergent SAEs, related TEAEs, TEAEs leading to drug withdrawn, 
fatal TEAEs (if any).  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 31 of 57  
6.12.1            Clinical Laboratory Evaluations  
For continuous laboratory parameters, descriptive statistics will be presented for each visit and 
for the changes from Baseline to each subsequent visit by [CONTACT_1570] , and the pooled 
buntanetap -treatment  group.  
 
Additionally, clinical laboratory parameters will be categorized as low, normal, or high 
according to laboratory range specifications and the number and percentage of participants  in 
each category will be presented in shift tables.  
Laboratory values that a re outside the normal range will also be flagged in the data listings, 
along with corresponding normal ranges.  
6.12.2   Electrocardiogram (ECG)  
12-lead ECGs are collected throughout the study. Observed change from baseline of ECG 
endpoints at each assessme nt timepoint will be summarized by [CONTACT_81591], and the 
pooled buntanetap -treatment  group. Observed QTc will also be categorized into the following 
categories (msec) and the number and percentage of subjects in each category will be 
summarized at each timepoint and the overall post -baseline maximum:  
• Observed: <=450, 451 -480, 481 -500, and >500; >450; >480  
• Change from Baseline: <=10, 11 -30, 31 -60, and >60; >[ADDRESS_586260] interpretation will al so be presented.  
6.12.3            Vital Signs  
Descriptive summaries (mean, SD,  SE, median, minimum, and maximum) of actual values and 
changes from Baseline will be calculated for systolic blood pressure, diastolic blood pressure, 
pulse, respi[INVESTIGATOR_697],  and oral temperature.  
6.12.4            Physical Examination Findings  
Physical examination data will be presented in the listings.  
6.12.5            Other Safety Parameters :  C-SSRS  
The number and percentage of participants  with suicidal ideation or suici dal behavior based on 
the C-SSRS will be summarized by [CONTACT_458867] -treatment  group . 
The distribution of responses for most severe suicidal ideation and most severe suicidal behavior 
during the participant ’s lifetime, during th e double -blind treatment period, and during the safety 
follow -up period will also be presented by [CONTACT_143496]. Supportive 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586261] suicidal ideation or suicidal behavior will also be provided.  
7 STUDY DRUG AND CONCOMITANT MEDICATIONS  
7.1 Identity  of IP and Comparator  
Buntanetap  will be pr ovided in size 1  orange  opaque hydroxypropyl methylcellulose ( HPMC , 
vegetarian source)  capsule shells .  Capsules contain  buntanetap (either 7.5mg, 15mg  or 30mg) 
formulated with inert inactive (non-lactose ) pharmaceutical excipi[INVESTIGATOR_458824].  Matching placebo capsules will be prepared with  the same 
inert inactive ingredients and look exactly like the buntanetap capsules.  
7.2 Dosage  
The study drug is to be taken orally;  one caps ule, once a day in the morning  right before  food, 
for [ADDRESS_586262] 80% of all doses  (across the 
12 weeks ).  Bottles  will be examined  in clinic  at each clinical visit to assess compliance .   
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 33 of 57 7.3 Packaging/Dispensing/Labeling  
The study drug ( buntanetap  capsules and placebo capsules) is manufactured under cGMP, in a 
manner to preserve the blind, i.e., identical color  and shape orange  opaque HPMC hard capsule 
shells and packaged 50 capsules per bottle.  
The investigational drug supply will be shipped directly to the clinical sites to dispense to 
participants.  
Sites should order IP only after successful confirmation of all eligibility criteria ( including  lab 
results) during screening period and well ahead  of baseline visit.  
The dosing schedule and storage requirements will be clearly explained to the participants and 
study partner  before dispensing the study drug.  
All packaging and labelling as well as the production of study medication will be in accord ance 
with cGMP  regulations . 
7.[ADDRESS_586263]  be stored at room temperature 
(not to exceed 25 °C/77°F), protected from light and moisture, in a locked , temperature -
controlled  area with restricted  staff access.  
7.[ADDRESS_586264] accountability records throughout the 
course of the study.  The responsible person(s) will document the amount of investigational 
product dispensed to and returned by [CONTACT_4317] .  All used and unused study drug containers 
must be returned to the site for accountability.  Once authorized by a clinical monitor, unused 
study drug  (including partially used bottles ) will be shipped back to the contracted depot for 
destruction.  
7.6 Compliance  
Site personnel will assess c ompliance base d on the amount of study drug dispensed to and 
returned by [CONTACT_3038] , together with any related information, including the administration 
of study drug by [CONTACT_458868]. Participants are encouraged  to maintain a 
minimum of 80% compliance with study drug administration across the [ADDRESS_586265] the participant to remind them of the 
dose regimen, to ensure that a good  level of compliance has been achieved.    
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586266] to unblind  a participan t’s treatment assignment. If the investigator needs 
the blind to be unmasked for a partici pant for SAE , the investigator can open the blind without 
prior consulting with  the Medical Monitor. If the blind is broken,  whether it be by [CONTACT_458869] t or for 
the welfare of the participant , the investigator MUST  contact [CONTACT_458870], together with the 
procedures for the management of the SAE .  Refer to the study procedures manual for detailed 
procedures related to breaking the blind and reporting . 
7.8     Concomitant Medications  
7.8.1 Prohibited Concomitant Medications  
Investigational agents are prohibited 4 weeks or five half -lives, whichever is greater, prior to 
entry and for the duration of the trial .  
Aducanumab/Aduhelm and Lecanemab/Leqembi are prohibited fo r 4 weeks or five half -lives, 
whichever is greater, prior to entry and for the duration of the trial.  
Initiation of prohibited medications during the course of the study is discouraged, however, if an 
excluded medication is initiated after screening, the s ite should consult with the Medical Monitor 
for further guidance.  
Buntanetap is mainly metabolized by [CONTACT_097]3A4 in vitro . Therefore, we recommend avoiding 
concomitant use of strong and moderate CYP3A4 inhibitor/inducers, examples see below 
according to FDA gu idance on drug development and drug interactions.  
CYP3A4 inhibitors  Itraconazole, Ketoconazole, Azamulin, Troleandomycin, Verapamil  
CYP3A4 inducers  Rifampi[INVESTIGATOR_2513]  
7.8.[ADDRESS_586267] 4 weeks before  screening and will continue to be stable throughout the study : 
• tricyclic antidepressants  
• antipsychotics  prescribed for any reason . However, the dos age must not exceed  the 
following for these medications:  
Quetiapi[INVESTIGATOR_050] ≤50 mg /day, risperidone ≤1.5 mg/day, olanzapi[INVESTIGATOR_050] ≤5 mg/day, and 
aripi[INVESTIGATOR_4253] ≤10 mg/day  
If the subject is on other antipsychotics besides the one s mentioned above, please consult              
the MM before screening the subject . 
• psychostimulants  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 35 of 57 Disco ntinuation and/or change of any of the above medication during the course of the study is 
discouraged, however, if necessary, the site should consult with the Medical Director and 
Sponsor for further guidance.  
This protocol allows concomitant treatment with anti -cholin esterase for [ADDRESS_586268] 24 hours after administration of the sedative.   
At this time, there is no controlled clinical data available for anyone receiving SARS -CoV -2 
(COVID 19) vaccination while being treated with buntanetap. However, based on the intended 
mechanism of actions and currently available data for these vaccine candidates and for 
buntanetap, it is not believed that there are specific risks to consider in participa nts participating 
in this study who have received SARS -CoV -2 (COVID19 ) vaccination or who are planning to 
receive the vaccination. As such, SARS -CoV -2 (COVID19 ) vaccination is not prohibited. If 
appropriate, SARS -CoV -2 (COVID19 ) vaccination should be consi dered as a concomitant 
medication . 
[ADDRESS_586269] meet the following criteria:  
1.  Diagnosis of Alzheimer’s disease according to NIA and NIA -AA criteria for probable AD 
(McKhann 2011 ). 
2. Male or female aged 55 – 85 years.  
3. MMSE 1 4-24. 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586270] with the participant (defined as at least 10 hours per week ) and  will accompany the 
participant to study visits at designated time s. 
5. Female participan ts of childbearing potential* must have a negative urine pregnancy test at 
Screeni ng, must be non -lactating  and must agree to use a highly effective method of 
contraception (i.e., a method resulting in a failure rate of less than 1% per year when used 
consistently and correctly) during the trial and for [ADDRESS_586271] dose of trial 
treatment, such as:  
• Oral, intravaginal,  or transdermal combined (estrogen plus progestogen) hormonal 
contraception associated with inhibition of ovulation  
• Oral, injectable,  or implantable progestogen -only hormonal contraception associated 
with inhibition of ovulation  
• Intraut erine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
• Vasectomized partner (a vasectomized partner is a highly effective contraception 
method provided that the partner is the sole male sexual partner of the partici pant,  and 
the absence of sperm has been confirmed. If not, an additional highly effective 
method of contraception should be used)  
• Sexual abstinence (sexual abstinence is considered a highly effective method only if 
defined as refraining from heterosexual  intercourse during the entire period of risk 
associated with the study treatment. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual lifestyle 
of the participant)  
*Non -childbeari ng potential includes surgically sterilized or postmenopausal with no 
menstrual bleeding for at least one year prior to study start . 
6. Male participants  must be sterile  or sexually inactive or  agree not to father a child during 
the study and one month aft er the last dose of study medication and  must agree to use a 
barrier method for contraception. Female partners of male participant  must  adopt a highly 
effective method of contraception with a failure rate of less than 1% per year when used 
consistently and correctly such as:  
• Oral, intravaginal,  or transdermal combined (estrogen plus progestogen) hormonal 
contraception associated with in hibition of ovulation  
• Oral, injectable,  or implantable progestogen -only hormonal contraception associated 
with inhibition of ovulation  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 37 of 57 • Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
7. Participant s can provide written informed consent . If PI [INVESTIGATOR_458825], their legally authorized representatives (LARs) can 
provide written informed consent.  Participants can comply with scheduled visits, and other 
study -related procedures to complete the study with the help of the study partner.  
 
8. No evidence of current suicidal ideation or previous suicide attempt in the past [ADDRESS_586272] 4 weeks prior to screening.  
a. Cholinesterase inhibitors and/or memantine medication  
 b. Anticonvulsant medications used for epi[INVESTIGATOR_458826], neuropathic pain 
indications.  
 c. Mood -stabilizing psychotropic agents, including, but not limited to, lithium .  
10. Adequate visual and hearing ability (physical ability to perform all the study assessments)  
as per investigator .  
 
11. Good general health with no disease expected to interfere with the study  as per investigator .  
 
8.[ADDRESS_586273] not be included in the study:  
1. Has a history of a psychiatric disorder such as schizophrenia, bipolar disorder,  or 
major depression according to the criteria of the most current version of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM). Mild depression or history of 
depression that is stable on treatment with a SSRI or SNRI medication at a stable d ose is 
acceptable.  
 
2. Has non -AD dementia, such as vascular dementia, Lewy body dementia, 
frontotemporal disease, Parkinson disease dementia , B12 and thyroid deficiency caused 
dementia .  
 
3.      History of a seizure disorder , if stable on medication is acceptable .  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 38 of 57  
4. Has a history or current evidence of long QT syndrome, Fridericia ’s formula 
corrected QT (QTcF) interval ≥ 450 ms for men and 460 ms for women , or torsades de 
pointes.  
 
5. Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening.  
 
6. Has uncontrolled Type -1 or Type -2 diabetes. A participant  with HbA1c levels up 
to 7.5% can be enrolled if the investigator believes the participant ’s diabetes is under 
contro l.  
 
7. Has clinically significant renal  (CKD -EPI <60 mL/min/BSA (body surface area)  
or hepatic impairment  (ALP > 2.[ADDRESS_586274] and/or total bilirubin > 2.[ADDRESS_586275]) .  
 
8. Has any clinically significant abnormal laboratory values. Participants  with liver 
function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) 
greater than twice the upper limit of normal will be excluded.  
 
9. Is at imminent risk o f self -harm, based on clinical interview and responses on the 
C SSRS, or of harm to others in the opi[INVESTIGATOR_308018]. Participants  must be 
excluded if they report suicidal ideation with intent, with or without a plan or method (e. 
g. positive res ponse to Items 4 or 5 in assessment of suicidal ideation on the C SSRS) in 
the past [ADDRESS_586276] year, except participants  
who underwent potentially curat ive therapy with no evidence of recurrence. ( Participants  
with stable untreated prostate cancer or skin cancers are not excluded).  
11. Alcohol / Substance use disorder, moderate to severe, in the  last [ADDRESS_586277] dose of an 
investigational agent was taken . 
 
13. Participants  with learning disability or developmental delay.  
 
14. Participants  whom the site PI [INVESTIGATOR_458827].  
 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 39 of 57 15. Participants  with a known allergy to the investigational drug or any of its 
components. Here are all the inactive ingredients of the IMP:  
Silicified Microcrystalline Cellulose  
Dibasic Calcium Phosphate Dihydrate  
Mannitol  
Magnesium Stearate  
Hypromellose e (capsule shel ls structure)  
titanium dioxide (opacifier of the capsule shells)  
 
16. Participant  is currently pregnant, breast -feeding and/or lactating.  
17.    Participant  is currently taking strong and moderate CYP3A4 inhibitors and/or 
inducers. See examples below:  
CYP3A4 
inhibitors  Itraconazole, Ketoconazole, Azamulin, Troleandomycin, 
Verapamil  
CYP3A4 
inducers  Rifampi[INVESTIGATOR_458828] -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586278] be done within a week. At PI’s 
discretion, re -testing  can be done within [ADDRESS_586279] Medical Monitor and sponsor for discussion on a  case-by-case basis. 
If/when  rescreening M MSE, the test has to be done at least 3 weeks apart from the previous one.  
Potential participants or their legally authorized representatives (LAR) if PI [INVESTIGATOR_458829],  must sign an informed consent form  
prior to administration of any study -related procedures . The informed consent process must be 
performed by [CONTACT_458] [INVESTIGATOR_458830] -investigator. Information 
regarding the participant ’s demographics, concurrent medications, an d medical history will be 
collected  along with cognitive assessments , physical examination, and neurological examination . 
Safety assessments will include an ECG that will need to be read locally  and reviewed  by [CONTACT_458871] . The clinical safety laboratory  blood  and urine  tests will be sent 
to a central lab for analysis . The screening safety laboratory tests will be comprise d of a 
metabolic panel, complete blood count,  and urina lysis as listed in Section 12.1.[ADDRESS_586280] be reviewed by [CONTACT_458872] ’s eligibility before proceed ing to Baseline.  
9.[ADDRESS_586281] three weeks after the 
participant’s  last MMSE test. The visit will consist of the following: admission pro cedures, 
including genetic material collection ( blood for ApoE genotype), PK Sampling / administration 
of first dose, and finally, discharge procedures.   
Fasting  state is required for safety laboratory tests, however, cognitive,  and functional 
assessments should not be administered when the participant  is in a fasted state . 
All baseline assessments should be performed on the same day. Details as below.  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 41 of 57 Participant s should arrive fasted in the morning after an overnight fas t. Clinical safety labs will 
be drawn and sent to the central lab for analysis.  
After safety lab, participants  will be provided low-fat light meal before completing functional 
and cognitive evalu ations, a physical and neurological exam, collecting vital signs, ECG, and 
reviewing and recording adverse events and concurrent medications. Sites should take detailed 
notes of the contents  of all meals provided to the participants . Following completion o f all these 
procedures, participants  who continue to meet all protocol inclusion criteria and no exclusion 
criteria should be randomized.  
If no medical or compliance concerns are identified, the participant  will move on to the PK 
sampling phase, which wil l entail the following procedures:  
1) Collect initial samples of blood (hour 0)  (12ml)  with venipuncture unless PI [INVESTIGATOR_458831] 2ml in a tube for ApoE genotype * and 10ml in a separate tube for PK.  
2) Administer first dose of assigned study drug after  the hour 0 sampling.  
3) Collect blood (10mL) at the 1hr, 2hrs and 4hrs  timepoint s. Blood should be taken within 
± 10 mins of times.  
4) Perform the final safety monitoring.  
* ApoE genotype sample can be collected along with any other blood draw  during this visit, as deemed appropriate 
by [CONTACT_976] .  
Prior to discharge from the clinic, vital signs should be recorded, and a review of AE(s) and 
concomitant medications should be conducted.  Participants  will be educated of the study drug 
compliance and stud y drug return. Upon determination by [CONTACT_737] (or qualified 
designee) that the participant  is stable, the participant will be discharged. If a participant 
experiences an unstable AE, please contact [CONTACT_458873] e 
course of action to be taken.  
 
9.[ADDRESS_586282] ional,  and cognitive  assessments,  safety  assessments,  and review  of concurrent  medications  
and adverse  events . Fasting  is required  for safety  laboratory  tests.   
After  safety  lab, participants  will be provided  low-fat light meal  before  completing  functional  
and cognitive  evaluations,  a physical  and neurological  exam,  collecting  vital signs,  ECG,  and 
reviewing  and recording  adverse  events  and concurrent  medications.  Sites  should  take detailed  
notes of the contents  of all meals  provided  to the participants . 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 42 of 57 Study  medication  compliance  will be reviewed  and discussed,  and reminders  given  about  the 
upcoming  end of trial visit.  The participant  should  be schedule d for the 12-week  clinic  visit.  
 
9.4 12 Week s Visit (End of Trial Visit ) 
Sites should remind participants [ADDRESS_586283]-visit 
phone follow -up will be conducted approximately 24 hours following discharge.  End of trial visit 
procedures include functional, and cognitive  assessments, safety assessments, and review of 
concurrent medications and adverse events that occur in clinic  and blood  collection . Fasting state 
is required for safety laboratory tests, however, cognitive, and functional assessments should not 
be administered when the participant  is in a fasted state . 
9.4.1 End of Trial Visit 
This constitutes the  participants ’ last clinical visit during the study. The end of trial  visit will 
consist of the following : admission  procedures , blood sampling , all psychometric and safety 
tests, and discharge  procedures . Fasting is required for safety laboratory tests.  
Participants  should arrive fasted  in the morning after an overnight fast. Clinical safety labs will 
be drawn and sent to the central lab for analysis.  
After safety lab, participants  will be provided a low-fat light meal before completing functional 
and cognitive evaluations, a physical a nd neurological exam, collecting vital signs, ECG, and 
reviewing and recording adverse events and concurrent medications. Sites should take detailed 
notes of the contents  of all meals provided to the participants .  
If no medical or compliance concerns are identified, the participant  will move on to the PK 
sampling phase, which will entail the following procedures:  
1) Collect initial samples of blood 10ml (hour 0) with venipuncture unless PI [INVESTIGATOR_458832].  
2) Administer last dose of assigned study drug  after the hour 0 sampling.  
3) Collect blood (10mL) at the 1hr, 2hrs and 4hrs timepoints. Blood should be taken within 
± 10 mins of times.  
4) Perform the final safety monitoring.  
Prior to discharge from the clinic, vital signs should be recorded, and a review of AE(s) and 
concomitant medications should be conducted.  Upon determination by [CONTACT_737] (or 
qualified designee) that the participant  is stable, the participant will be discharged. If a 
participant experiences an unstable AE, please contact [CONTACT_458874].  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586284] End of Trial Visit 24-Hour Phone  Follow -up 
Approximately 24  hours  following the end of trial visit the participant  will be contact[CONTACT_458875] ’s well -being and to query about any new A Es. 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 44 of 57 10 EARLY TREATMENT/STUDY DISCONTINUATION  
The investigators at each site will make every reasonable effort to maximize participant  
retention. However, if an investigator removes a participant  from treatment or study, or if a 
participant  declines further treatment or study participation, an early discontinuation visit will be 
completed as soon as possible following discontinuation .  
Participants  who discontinue from the study prior to completing all protocol procedures  may be 
replaced in consultation with the Sponsor.  
10.[ADDRESS_586285]  also be 
discontinued from treatment/study for reasons such as the fol lowing:  
• Adverse experience: The participant  has experienced an adverse event that, in the opi[INVESTIGATOR_8574], requires early discontinuation . This may include abnormal laboratory 
values.  
• Death . 
• Safety risk: Any participant  who becomes a safety risk  to themselves  during the trial will 
be withdrawn.  
• Protocol violation: The participant  fails to meet protocol entry criteria during the study 
after being randomized or does not adhere to protocol requirements.  * 
• Development of sui cidal or homicidal ideation requiring hospi[INVESTIGATOR_458833] . 
• Consent is withdrawn. The participant s or their LARs wishes to withdraw from the study.  
• The study is terminated by [CONTACT_1034]/Coordinating Center, alone or at the 
recommendation of the Data Safety Monitoring Board.  
• Lost to follow up.  Participant  could not be recalled back to conduct follow up visits.  
* The line item above requires the participant to continue to meet study entry criteria after 
randomization. This means that assessments conducted at visits post -randomization, such as vital 
signs, ECG, and laboratory tests, with results that fall outside of  the parameters outlined in the 
Inclusion/Exclusion criteria must be discussed with the Medical Monitor and Study Team.  
The investigator and Medical Monitor will review the case to determine whether the participant 
must be discontinued from the study base d on the abnormal value or if it is safe for the 
participant to continue treatment.   
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 45 of 57 11 STUDY -SPECIFIC INSTRUMENTS  
The following instruments will be employed to measure  states of function, dementia, and 
movement .   
• Alzheimer’s Disease Assessment Scale –Cogni tive Subscale (ADAS -Cog11)  
• Mini -Mental State Examination  (MMSE ) 
• Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS -ADL)  
• Clinical  Global Impression of Change ( ADCS -CGIC) 
• Digital Symbol Substitution Test (DSST )  
12 STUDY -SPECIFIC PROCEDURES  
12.1 Safety Assessments  
Safety will be evaluated by  [CONTACT_458876], 
including any A Es/SAEs as reported by [CONTACT_458877], or using  
concomitant medication durin g the study.  
12.1.1  Physical and Neurological Examination  
A medically qualified professional will perform a physical examination that consists of a review 
of the major body systems (i.e., skin, head/ears/eyes/nose/throat (HEENT), cardiovascular, 
pulmonary, abdome n, musculoskeletal, and extremities) and a neurological examination which 
will include an assessment of cranial nerves, strength, coordination, reflexes, sensation, t remor, 
gait and mental status. Assessments of height, weight, and vital signs (systolic an d diastolic 
blood pressure, pulse, temperature, and respi[INVESTIGATOR_1516]) are included.  
12.1.2  Electrocardiogram (ECG)  
An appropriately qualified individual will conduct a  standard [ADDRESS_586286]  be reviewed, signed, and dated by [CONTACT_7880] (or a medically qualified  
individual d elegated by [CONTACT_168761]). Those with clinically significant ECG findings will be 
referred for follow -up as deemed appropriate by [CONTACT_458878] t he 
study.  
  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586287] for the same 
scales d uring the whole study. Additionally , the PI [INVESTIGATOR_458834]. Additional key personnel will be required, as 
outlined in the procedure manual.   
14 ADVERSE EVENTS  (AES)   
14.1 Definition  
An AE is defined as per the US Code of Federal Regulation, Title 21, Part 312.32  (2016) and 
ICH E2A: International Conference on Harmoni zation - Tripartite Guideline: Clinical Safety 
Data Management: Definitions and Standards for Expedited Repor ting (1994) .  
Any untoward medical occurrence in a participant  or clinical investigation participant  
administered a pharmaceutical product  which does not necessarily have to have a  causal 
relationship with this treatment . 
Collection of adverse events will begin once informed consent is signed and will continue until 
the 24-hour phone follow -up after the participant  is discharged from the clinic at the end of study 
visit or discontinues from the study .  Adverse events include but are not limited to: (1) wors ening 
or change in nature, severity, or frequency of conditions or symptoms present at the start of the 
study; (2) Participant  deterioration due to primary illness; (3) intercurrent illness; and (4) drug 
interaction. An abnormal laboratory value will only be reported as an AE if the investigator 
considers it clinically  significant, or if it leads to the Participant  being withdrawn from the study.  
The investigator should attempt to establish a diagnosis of the event based on signs, symptoms, 
and or other cli nical information. In such cases, the diagnosis should be documented as the AE 
and not the individual signs or symptoms. Symptoms and conditions present at the beginning of 
the study will be characterized, so that A Es can be defined as any new symptom, or any increase 
in frequency or severity of an existing symptom. Adverse events should be described with 
medical terminology so that the event can be matched against a medical coding dictionary, such 
as MedDRA (Medical Dictionary for Regulatory Activities).  
Investigators should report their assessment of the potential relatedness of each AE to the 
protocol procedure, and to the investigational product, and/or drug delivery system used in the 
protocol.   
Following questioning and evaluation, all A Es, whether determined to be related or unrelated to 
the study drug by a medically qualified site PI [INVESTIGATOR_458835] ’s records, in accordance with the investigator’s normal clinical practice, and on the 
AE case report form .  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586288] subsided, the 
conditions are considered medically stable, or the participants  are no longer available for follow 
up. Participants  who discontinue due t o adverse experiences will be treated and followed 
according to established medical practice. All pertinent information will be entered into the 
eCRF. Adverse events will be reported to the Medical Monitor, Sponsor, and  DSMB , per 
Coordinating Center SOPs a nd the DSMB Charter.  
15 SERIOUS ADVERSE EVENTS (SAE)  
15.1 Definition  
An SAE is defined as per the US Code of Federal Regulation, Title 21, Part 312.32  (2016) and 
ICH E2A: International Conference on Harmoni zation - Tripartite Guideline: Clinical Safety 
Data Manag ement: Definitions and Standards for Expedited Reporting (1994) . 
An adverse event or suspected adverse reaction is considered “serious ” if, in the view of either 
the investigator or Sponsor, it results in any of the following outcomes: Death, a life -threatening 
adverse event, inpatient hospi[INVESTIGATOR_1081], a persistent or 
significant incapacity or substantial disruption of the abi lity to conduct normal life functions, or a 
congenital anomaly/birth defect. Important medical events that may not result in death, be life -
threatening, or require hospi[INVESTIGATOR_708], based upon appropriate 
medical judgment, the y may jeopardize the participant  and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such medical 
events include allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the 
development of drug dependency or drug abuse.  
15.2 Reporting SAEs  
Collection of serious adverse events will begin once informed consent is signed (regardless of 
study drug exposure) and will be monitored throughout the trial .  All SAEs  must be reported to 
the Medical Monitor  and the Sponsor  within [ADDRESS_586289] Directors, 
which will lead to the initiation of the creation of the report. A notification will be sent to all 
participating sites and the DSMB once the report is available. Sites will inform their IRB of the 
event based on local IRB req uirements. The Sponsor is the IND holder  and is responsible for 
submitting any SAEs according to the FDA reporting requirements.    
  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 49 of 57 16 SUSPECTED UNEXPECTED SERIOUS , ADVERSE REACTION  
16.1 Definition  
A suspected unexpected serious adverse reaction (S[LOCATION_003]R) is an AE that is assessed as serious, 
related,  and unexpected.  
16.2 Reporting of Suspected Unexpected Serious Adverse Reactions  
The Sponsor is responsible for informing the FDA and IRB of any individual case reports of SAEs 
that are determined to be reportable by [CONTACT_1034] (S[LOCATION_003]Rs). The Investigator will ensure that 
all relevant information is provided to the Sponsor to allow the  Sponsor to meet their obligations 
to report the S[LOCATION_003]R to the FDA and IRB. For a S[LOCATION_003]R that is fatal or life -threatening, this should 
be reported as soon as possible and not later than [ADDRESS_586290]  
Not applicable.  
18 PRECAUTIONS/OVERDOSE  
If a participant  receives a dose exceeding 200 mg of buntanetap , the dose may be considered toxic. 
Since this is a double -blind  study, if a participant  swallows 7 or more capsules  with the assumption 
of them being in the 30mg buntanetap  group , this will be considered an overdose, and in such case, 
the information will b e collected following the same timeframe and procedures as for a SAE, even 
if the overdose is not associated to any AE/SAE. No specific treatment is recommended apart from 
appropriate supportive measures.  
[ADDRESS_586291] visit, if they believe that conception occurred during their participation in the study.  
A pregnancy as such is not an AE, unless there is a possibility that the study drug  has interfered 
with the efficiency of any contraceptive measures. However, the Investigator should report 
pregnancies according to the procedures and timelines described for reporting of SAEs ( Section 
15.2). The pregnancy report form should be u sed instead of the SAE form.  
The pregnant participant  or partner will be followed until the end of the pregnancy. Any 
complication during the  pregnancy should preferably be reported as an AE or SAE (if it fulfils 
SAE criteria). The outcome of the pregnancy  must be reported on the pregnancy report form. Any 
spontaneous abortion, stillbirth, birth defect/congenital anomaly, death, or other serious infant 
condition must be reported and followed up as an SAE . 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586292]  (DSMB)  
An independe nt DSMB will review the safety information from the study  on an ongoing basis. 
The DSMB, will identify the study -specific data parameters and format of the information to be 
reported , as well as the timing of reports based on the enrollment status of the study . The DSMB 
will initially be provided with data blinded to treatment status, but they may request unblinded  
data if there is a safety concern.  
Additionally, the DSMB will be informed of the occurrence of any serious adverse events within 
[ADDRESS_586293] of the study. These may include a mending safety monitoring procedures, modifying the 
protocol or consent, terminating the study,  or continuing the study as designed. Using the Safety 
Review Process (review of lab data, vitals, and adverse events) and the DSMB, there is 
substantial oversig ht and case review to alert the investigators, in a timely manner, to any  safety 
issues that may arise. Further details  will be provided in  the DSMB charter.  
21 RECORDING AND COLLECTION OF DATA  
21.1 Electronic Case Report Form  (eCRF)  
The PI [INVESTIGATOR_458836] d all data collected (either written or electronic record of data). 
Written or electronic data of record must be entered into the eCRF provided for that purpose. In 
some instances , no prior written or electronic record of data may exist,  and data recorded directly 
into the eCRF is considered source data. The site will be suitably trained on the use of the eCRF 
and appropriate site personnel will be authorized to provide electronic signatures. The PI [INVESTIGATOR_458837].  
All site entries will be made in a secured eCRF,  and the PI [INVESTIGATOR_458838] w the record for 
completeness. If corrections are necessary to the eCRFs, the PI [INVESTIGATOR_458839].  
Completed eCRFs will be submitted according to provided instructions and  reviewed by [CONTACT_458879]. If necessary, data correction requests will 
be generated for resolution by [CONTACT_3452].   
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-[ADDRESS_586294] by [CONTACT_3486], research staff, 
and the Coordinating Center and/or sponsoring institution and their agents. This confidentiality  is 
extended to cover testing of biological samples and genetic tests in addition to the clinical 
information relating to participants . 
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No infor mation concerning the study, or the data will be released to any 
unauthorized third party, without prior written approval of the sponsoring institution. Authorized 
representatives of the sponsoring institution may inspect all documents and records required  to 
be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or 
hospi[INVESTIGATOR_307]) and pharmacy records for the participants  in this study. The clinical study site will 
permit access to such records. Any data, specimens, forms, reports, video/audio recordings, and 
other records that leave the site will be identified only by a participant  identification number 
(Participant  ID, P ID) to maintain confidentiality. All records will be kept in a locked file cabinet. 
All computer entry and networking programs will be done using PI[INVESTIGATOR_34107]. Information will not 
be released without written permission of the participant , except as necessary  for trial -related 
monitoring, audits, IRB review, and regulatory inspection(s), where direct access to source 
data/documents will be provided.  
Information about study participants  will be kept confidential and managed according to the 
requirements of the General Data Protection Regulation ( GDPR ) of 2018, and the Health 
Insurance Portability and Accountability Act (HIPAA) of 1996.  
If a participant  revokes authorization to collect or use  protected health information  (PHI), the 
investigator, by [CONTACT_5151], r etains the ability to use all information collected prior to the 
revocation of participant  authorization. Each site PI, under the guidance of his/her IRB, is 
responsible for ensuring that all applicable GDPR/HIPAA regulations and laws are met.  
22 ETHICS AND R EGULATORY CONSIDERATIONS  
22.1 Good Clinical Practice  
This study will be conducted in compliance with the protocol and accordance with Good Clinical 
Practice (GCP) guidelines, as defined by [CONTACT_8639] (ICH) 
Guideline, Topic E6,  the ethical principles of the latest revision of the Declaration of Helsinki as 
adopted by [CONTACT_58424], and all other applicable local regulatory 
requirements and laws.  
Study personnel involved in conducting this study will be qualified by [CONTACT_8640], training , and 
experience to perform their respective task(s) in accordance with GCP.  
No study document shall be destroyed without prior written agreement between the Coordinating 
Center and the investigator. Should the investigator wish to as sign study records to another party 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 52 of 57 or move them to another location, he/she may do so only with the prior written consent of the 
Coordinating Center.  
22.[ADDRESS_586295] (IRB ) 
In the US, IRBs  must be constituted, and their authority delegated through the institution’s 
normal process of governance according to applicable State and Federal requirements for each 
participating location. Each participating institution must provide for the review an d approval of 
this protocol and the associated informed consent documents and recruitment material by [CONTACT_458880]. Any amendments to the protocol or consent materials 
must also be approved before they are placed into use. In  the US, only institutions holding a 
current US Federal wide Assurance (FWA) issued by [CONTACT_200315].  
The investigator must obtain approval from the IRB for all subsequent protocol amendments and, 
when warranted, changes to the informed consent docu ment. Protocol and informed consent 
form amendments can be made only with the prior approval of the Coordinating Center. The 
investigator shall notify the IRB of deviations from the protocol or SAE s occurring at the site, in 
accordance with local procedure s. 
22.[ADDRESS_586296] 
(HIPAA ) Compliance  
Informed consent will be obtained in accordance with 21CFR§50.25, and ICH GCP . Applicable 
HIPAA privacy notifications will be implemented,  and HIPAA /GDPR  authorizations signed 
before protocol procedures are conducted . Information should be given in both oral and written 
form as deemed appropriate by [CONTACT_198991]’s IRB.   
Prior to the beginning of the trial, the investigator must  obtain  the IRB’s written approval of  the 
informed consent form and any other written information to be provided to participants  and their 
LAR if LAR is required . Consent forms must be in a language fully comprehensible to the 
prospective participants . Participants  and their LARs if LAR is required  will be given ample 
opportunity to inquire about the details of the study. Prior to a participant ’s participation in the 
trial, the written informed consent form should be signed and personally dated by [CONTACT_458881]. Participants  will be provided a copy of the signed ICF.  
The informed consent will not only cover consent for the trial itself, but for the genetic 
samples/data/storage and biomarker samples/data/storage as well. Consent forms will specify 
that DNA and biomarker samples are for research purposes only; the tests on the DNA and 
biomarker samples are not diagnostic in nature , and are part of the study an alysis,  and 
participants  will never receive results.  
  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 53 of 57 23 STUDY MONITORING   
The clinical monitor is responsible for inspecting the case report forms (CRFs) and source 
documentation at specific time points throughout the study to verify adherence to the protoc ol, 
completeness and accuracy of the data, and adherence to local regulations on the conduct of 
clinical research.  
The monitor will visit the study site on a regular basis to ensure that the study is conducted and 
documented in accordance with this protoco l, ICH GCP guidelines, regulatory requirements , and 
any study specific documents such as CRF completion guidelines.   Monitoring visits will be 
conducted to confirm that e.g.:  
• The investigational team is adhering to the study protocol  
• Informed consent has b een obtained from all participants  
• AEs have been reported as required  
• Data are being accurately recorded in the CRF  
• Study drug  is being stored correctly and drug accountability is being performed on an on -going basis  
• Facilities are, and remain, acceptable throughout the study  
• The Investigator and the site are receiving sufficient information and support throughout the study  
Moreo ver, during monitoring visits the data recorded in the CRF, source documents and other 
study -related records will be compared against each other to ensure accurate data that reflect the 
actual existence of the participant  in the study , i.e., source data ve rification. The Site Investigator 
will cooperate in the monitoring process by [CONTACT_458882], source 
documents and other necessary documents at the time of the monitoring visits. Site Investigator 
will promptly address any matters bro ught to his/her attention by [CONTACT_2037].  
24 AUDIT  
In accordance with ICH E6 R2 (Good Clinical Practices) representatives of the Contract 
Research Organization ( CRO) and/or Sponsor and/or regulatory agency may select this study for 
audit. The investigator and  study staff are responsible for maintaining the site master file 
containing all study -related regulatory documentation that will be suitable for inspection at any 
time by [CONTACT_2024], the Sponsor, its designees, a regulatory authority (i.e., FDA)  and/or an IR B. 
Inspection of site facilities (e.g., pharmacy, laboratories) to evaluate the trial conduct and 
compliance with the protocol may also occur.  
[ADDRESS_586297] RETENTION  
The Sponsor shall retain the records and reports required for 2 years after a marketing 
application is approved for the drug; or, if an application is not approved for the drug, until 2 
years after shipment and delivery of the drug for investigational use is discontinued and FDA has 
been so notified  (21CFR §312.57) .  
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 54 of 57 26 LITERATURE CITED  
Chen XQ, S.A., Pearn M, Maccecchini M, Mobley W, Targeting increased levels of APP in 
Down syndrome: Posiphen -mediated reductions in APP and its products reverse endosomal 
phenotypes in the Ts65Dn mouse model. Alzheimer's & dementia , 2020.  
Fang C, Hernandez P, Liow  K, Damiano E, Zetterberg H, Blennow K, Maccecchini M. (2022). 
Buntanetap, a novel translational inhibitor of multiple neurotoxic proteins, proves to be safe and 
promising in both Alzheimer’s and Parkinson’s patients. Journal of Prevention of Alzheimer’s 
Disease . 2022 . 
Folstein  M.F., Folstein, S.E., McHugh, P.R. (1975). “Mini -mental state ”. A practical method for 
grading the cognitive state of patients for the clinician. Journal of Psychiatric Research,  12(3), 
189-198. 
Kadir A., Andreasen N., Almkvist O., Wall A., Forsberg A., Engler H., HagmanG., Lärksäter 
M.,Winblad B., Zetterberg H., Blennow K., Längström B., Nordberg A. (2008). Effect of 
Phenserine Treatment on Brain Functional Activity and amyloid in Alzheimer ’s disease . Ann 
Neurol  621-631. 
Kuo YM, Nwankwo EI, Nussbaum RL, Rogers J, Maccecchini ML (2019). Translational 
inhibition of α -synuclein by [CONTACT_458883]. Am J Neurodegener Dis 8(1):1 -15. 
Lilja  A.M., Röjdner J ., Mustafiz T., Thome C.M., Storelli E., Gonzalez D., Lithner C.U., Greig 
N.H., Nordberg A., Marutle A. (2013) Age -Dependent Neuroplasticity Mechanisms in 
Alzheimer Tg2576 Mice Following Modulation of Brain Amyloid -β Levels .  PLoS  ONE 8(3): 
e58752. doi:10.1371/journal.pone.0058752 . 
Maccecchini ML, Chang MY, Pan C, John V, Zetterberg H, Greig N (2012). Posiphen as a 
candidate drug to lower CSF amyloid precursor protein, amyloid -b peptide and s levels: target 
engagement, tolerability  and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry, 
83:894 -902.  
 
Marutle  A, Ohmitsu M, Nilbratt M, Grieg NH, Nordberg A, Sugaya K (2007). Modulation of 
human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by [CONTACT_458884]. 
PNAS  104(30).  
 
McKhann  GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas GH, Klunk WE, 
Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo 
MC, Thies B, Weintraub S, Phelps CH (2011). The diagnosis of dementia due to Al zheimer’s 
disease: recommendations from the National Institute on Aging - Alzheimer’s Association 
workgroups on diagnostic guidelines for Alzheimer’s disease. Alzeheimrs Dement  7(3):263 -9. 
 
Protocol ANVS -[ZIP_CODE]   Ver. 3.1; 09-25-2023  
Confidential   Page 55 of 57 Teich AF, Sharma E, Barnwell E, Zhang H, Staniszewski A, Utsuki T, Padmaraju V, Mazell C, 
Tzekou A, Sambamurti K, Arancio O, Maccecchini ML (2018). Translational inhibition of APP 
by [CONTACT_458885]: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse.  
Alzheimers Dement Transl Res Clin Interv 4:37–45. 
 
Wechsler  D (2008). Wechsler Adult Intelligence Scale —Fourth Edition Administration and 
Scoring Manual. San Antonio, TX: Pearson ( only available under license agreement ) 
Yu QS, Reale M, Kamal M .A., Holloway H .W., Luo W ., Sambamurti K ., Ray B ., Lahiri D .K., 
Rogers JT, Greig NH  (2013). Synthe sis of the Alzheimer drug posiphen into its primary 
metabolic products (+) -N1-norposiphen, (+) -N8-norposiphen and (+) -N1,N8 -bisnor posiphen, 
their inhibit ion of amyloid precursor protein, a Synuclein synthesis, interleukin -1β release and 
cholinergic action. Antiinflamm Antiallergy Agents Med Chem.  12:117 -28. 
Mehta  CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a 
practical guide with examples. Stat Med. 2011;30(28):3267 -3284.  
Chen  YH, DeMets DL, Lan KK. Increasing the sample size when the unblinded interim result is 
promising. Statistics in Medicine. 2004; 23(7): 1023 -1038  
Y.H. Joshua Chen , Shuai S. Yuan & Xiaoming Li (2018). Statistical Inference following sample 
size adjustment b ased on the 50% -conditional -power principle. Journal of Biopharmaceutical 
Statistics. 28:3, 575 -587, DOI: 10.1080/10543406.2017.1372766  
 
 
 
Protocol ANVS -[ZIP_CODE]     Ver. 3.1; 09-25-2023  
Confidential   Page 56 of 57 APPENDIX 1: SCHEDULE OF EVENTS  
Study Period  Screening/Baseline  At-Home Treatment  Unscheduled 
Visitk Early 
Discontinuation 
Visit  
Visit Timing Day -42 to 0  6 weeks ± 7 days  12 weeks ± 7 days  
(end -of-trial) b   
Procedure  Screening j 
(up to 42 days 
before Day 0)  Baseline (Day 
0) Clinic Visit  
- Clinic Visit  
- Clinic Visit   
Clinic Visit  
Informed consent  X      
Inclusion and exclusion criteria  X X     
Demography information  X      
Full physical and neurological 
examination  X X X X X X 
Height, Weight, BMI  X      
Medical and psychiatric history (includes 
substance use)  X      
Urine pregnancy test (WOCBP only)  X X X X X X 
MMSE   l X X  X  X 
ADCS -CGIC   Xd Xe Xe  Xe 
ADAS -Cog11   X X X  X 
ADCS -ADL   X X X  X 
DSST   X X X  X 
C-SSRS  X X X X X X 
Safety l aboratory tests c X X X X X  X 
12-lead ECG  X X X X  X 
Vital signsa X X X X X X 
Protocol ANVS -[ZIP_CODE]     Ver. 3.1; 09-25-2023  
Confidential   Page 57 of 57 Study Period  Screening/Baseline  At-Home Treatment  Unscheduled 
Visitk Early 
Discontinuation 
Visit  
Visit Timing Day -42 to 0  6 weeks ± 7 days  12 weeks ± 7 days  
(end -of-trial) b   
Procedure  Screening j 
(up to 42 days 
before Day 0)  Baseline (Day 
0) Clinic Visit  
- Clinic Visit  
- Clinic Visit   
Clinic Visit  
Randomization   X     
Genetic sample (ApoE)   X     
Study intervention   Xg Xh XI   
Study intervention compliance review    X X   
AE/SAE  review  X X X X X X 
Concomitant medication review  X X X X X X 
PK sampling   X  X   
Sampling for blood biomarkers   X  X   
24-hour phone follow -up  X X X X X 
a Vital sign  will include sitting blood pressure, pulse, temperature, respi[INVESTIGATOR_1487].  
b Participants that drop out before the initial 9 weeks of study treatment will complete the Early Discontinuation visit and participants that drop out after 
the initial 9 weeks of  study treatment will complete  the End -of-Trial visit.  
c Safety labs should be taken fasted.  
d ADCS -CGIC evaluation only . 
e ADCS -CGIC evaluation and scoring the scale . 
g Participants  are given one pi[INVESTIGATOR_458840]-dose (0h) blood samples and the pi[INVESTIGATOR_458841] 6 weeks at the end of the visit.  
h Participants  are given pi[INVESTIGATOR_458841] 6 weeks at the end of the visit.  
I Participants  are given one pi [INVESTIGATOR_458842]-dose (0h) blood samples.  
J At PI’s discretion, re -testing  can be done within [ADDRESS_586298] Medical Monitor and 
sponsor for discussion on a  case-by-case basis. If/when  rescreening MMSE, the test must  be done at least [ADDRESS_586299] 3 weeks apart.  